Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23601690)

1.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.

2.

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.

3.

[Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].

Fan LK, Wang ZW, Hua BL, Su W, Wang SJ, Zhao YQ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):551-4. Chinese.

4.

Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Batlle J, Gómez E, Rendal E, Torea J, Lourés E, Couselo M, Vila P, Sedano C, Tusell X, Magallón M, Quintana M, González-Boullosa R, López-Fernández MF.

Ann Hematol. 1996 May;72(5):321-6.

PMID:
8645745
5.

Alloantibodies to factor VIII in haemophilia.

Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Butenas S, Mann KG, Green D.

Haemophilia. 2011 Jul;17(4):636-40. doi: 10.1111/j.1365-2516.2010.02468.x. Epub 2011 Feb 7.

PMID:
21299745
6.

Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.

Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, Gill J, Leissinger C, Soucie JM; and the Hemophilia Inhibitor Research Study Investigators.

Am J Hematol. 2015 Jul 3. doi: 10.1002/ajh.24104. [Epub ahead of print]

PMID:
26147783
7.

Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.

Kershaw GW, Chen LS, Jayakodi D, Dunkley SM.

Thromb Res. 2013;132(6):735-41. doi: 10.1016/j.thromres.2013.09.018. Epub 2013 Sep 21.

PMID:
24119613
8.

Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.

Kraiem I, Hadhri S, El Omri H, Sassi R, Chaabani W, Ennabli S, Skouri H.

Ann Biol Clin (Paris). 2012 Nov-Dec;70(6):659-65. doi: 10.1684/abc.2012.0765.

PMID:
23207810
9.

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.

PMID:
25354263
10.

Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.

Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.

Haemophilia. 2014 Jan;20(1):e7-14. doi: 10.1111/hae.12309.

PMID:
24354488
11.

Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.

Towfighi F, Gharagozlou S, Sharifian RA, Kazemnejad A, Esmailzadeh K, Managhchi MR, Shokri F.

Acta Haematol. 2005;114(2):84-90.

PMID:
16103630
12.

Nijmegen-Bethesda assay to measure factor VIII inhibitors.

Duncan E, Collecutt M, Street A.

Methods Mol Biol. 2013;992:321-33. doi: 10.1007/978-1-62703-339-8_24.

PMID:
23546724
13.

[Diagnosis and influence factor of antibody to coagulation factors in hemophilia].

Zhao XA, Liu SX, Li F, Liu YG, Ren YP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):971-4. Chinese.

PMID:
21867626
14.
15.

Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.

Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group.

Int J Hematol. 2006 Aug;84(2):158-65.

PMID:
16926139
16.

A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant.

Blanco AN, Alcira Peirano A, Grosso SH, Gennari LC, Pérez Bianco R, Lazzari MA.

Haematologica. 2002 Mar;87(3):271-8.

17.

Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.

Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J.

Haemophilia. 2013 Jan;19(1):106-12. doi: 10.1111/j.1365-2516.2012.02903.x. Epub 2012 Jul 5.

PMID:
22762454
18.

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators.

Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.

19.

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.

Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, Giles AR, Yoshioka A.

J Thromb Haemost. 2006 Feb;4(2):377-84.

PMID:
16420569
20.

Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII).

Santoro C, Iorio A, Ferrante F, Pallotta A, Pignoloni P, Biondo F, Agnelli G, Mazzucconi MG.

Haemophilia. 2009 May;15(3):779-87. doi: 10.1111/j.1365-2516.2009.01983.x. Epub 2009 Feb 27.

PMID:
19298379
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk